Publications, Pharmaceutical

Ophthalmic Squeeze Dispenser (OSD): Does One Size Fit All?

Controversy remains over the inclusion of preservatives in eye drops since with prolonged use even approved additives can potentially exacerbate eye conditions such as dry eye.

This article discusses Aptar Pharma’s Ophthalmic Squeeze Dispenser within the context of growing requirements for ophthalmic drug delivery devices for preservative-free formulations, such as artificial tears. The principle of operation of the device is discussed along with features that impact formulation development. The Ophthalmic Squeeze Dispenser is a flexible and convenient ophthalmic drug delivery device for multidose preservative-free formulations that patients find intuitively easy to use.
Aptar Pharma offer expert advice on formulation optimization for this system and provide 100% validated in-process manufacturing controls to safeguard its integrity.

Download Publication
Author(s): Degenhard Marx Matthias Birkhoff
Drug Development & Delivery
1 Oct 2015

The discussion about the use of preservatives in eye drops is still controversial, but more and more evidence supports the use of unpreserved eye drops for treatment of chronic diseases. For example, dry eye, a condition in which the tear film is impaired, is increasingly more recognized as an inflammatory disease. Treatment with preserved eye drops may worsen symptoms. For the treatment of mild symptoms, the use of non-irritating or unpreserved artificial tears is recommended, while as for more severe cases, the use of an anti-inflammatory principle will become the standard treatment.

The same recommendation for restricted use of preservatives applies for glaucoma, which requires a treatment for the rest of life. Baudoine et al have shown that the risks for glaucoma patients to experience severe local side effects increases with the number of preserved eye medications taken in parallel.1 Combination products that reduce the number of necessary medications or the use of unpreserved eye drops will certainly help suffering patients and will also increase adherence to the prescribed treatment schedule. At least in Europe, the authorities have recognized the issue, and the European Medical Agency (EMA) pushes, for example, the use of unpreserved ophthalmic formulations, most recently in a guideline on pediatric medicine.

Recognizing the trend toward preservative-free topical drugs, in 2006, Aptar Pharma started the development of the Ophthalmic Squeeze Dispenser (OSD), a multi-dose device designed for unpreserved eye drops.3 The system is designed in a common squeeze bottle shape to ensure user acceptance. The first commercial product registered under the European Medical Device Directive using the OSD as primary packaging was VISMED Multi, an artificial tear product by Swiss Eye Care expert TRB Chemedica, introduced to the market in 2011. To date, more than 25 million OSDs were sold as preservative-free multi-dose systems for several products, and many new projects are on the way. The key question we will answer in this review is how a single device can fit a wide range of formulations for different conditions and diseases?

Request Access

Close

Requesting access to Ophthalmic Squeeze Dispenser (OSD): Does One Size Fit All?.

  • This field is for validation purposes and should be left unchanged.
Back To Top